965 Results

People

  1. Pasternak
    Pasternak
  2. Schwartz
    Schwartz
  3. Marks
    Marks
  4. Rosen
    Rosen
  5. Scher
    Scher
  6. De Stanchina
    De Stanchina
  7. Moore
    Moore
  8. Motzer
    Motzer
  9. Chou
    Chou
  10. Saltz
    Saltz

Groups

  1. Department of Medicine (366)
  2. GSK Faculty (226)
  3. Sloan Kettering Institute Faculty (208)
  4. Solid Tumor Oncology Division (204)
  5. Molecular Pharmacology and Chemistry Program Faculty (127)
  6. Hematologic Malignancies, Division of (119)
  7. Sloan Kettering Institute Postdocs (113)
  8. Center for Hematologic Malignancies (108)
  9. Surgery (103)
  10. Survivorship Research (91)
  1. "drug effect"
Formats
  1. Journal Article (897)
  2. Review (24)
  3. Conference Paper (23)
  4. Editorial (10)
  5. Research Letter (8)
  6. Guidelines (2)
  7. Book Section (1)
Groups
  1. Department of Medicine (366)
  2. GSK Faculty (226)
  3. Sloan Kettering Institute Faculty (208)
  4. Solid Tumor Oncology Division (204)
  5. Molecular Pharmacology and Chemistry Program Faculty (127)
  6. Hematologic Malignancies, Division of (119)

More Groups

People
  1. Gavril Pasternak (27)
  2. Gary Schwartz (21)
  3. Ting-Chao Chou (21)
  4. Paul Marks (20)
  5. Howard Scher (18)
  6. Neal Rosen (18)

More People

Years
  1. 2025 (28)
  2. 2024 (85)
  3. 2023 (10)
  4. 2022 (13)
  5. 2021 (10)
  6. 2020 (19)

More Years

Publications
  1. Journal of Clinical Oncology (43)
  2. Clinical Cancer Research (40)
  3. Blood (25)
  4. Cancer Research (22)
  5. Proceedings of the National Academy of Sciences of the United States of America (19)
  6. Nature Communications (14)

More Publications

Publishers
  1. American Association for Cancer Research (89)
  2. Nature Publishing Group (78)
  3. Elsevier Inc. (73)
  4. Springer (47)
  5. American Society of Clinical Oncology (44)
  6. Elsevier Science, Inc. (39)

More Publishers

Results (965)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: The MyCheckpoint randomized clinical trial
    Journal Article

    Richard, S.; Lesokhin, A. M.; Paul, B.; Kaufman, J. L.; Pianko, M.; Biran, N.; Vij, R.; Doxie, D. B.; Azeem, M. I.; Martillo, M.; more...
    Nature Cancer (2024)

    Fulltext@MSK | Save
  • CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
    Journal Article

    Skoulidis, F.; Araujo, H. A.; Do, M. T.; Qian, Y.; Sun, X.; Cobo, A. G.; Le, J. T.; Montesion, M.; Palmer, R.; Jahchan, N.; more...
    Nature (2024)

    Fulltext@MSK | Save
  • ERK1/2 pro-survival signalling is suppressed by pirtobrutinib in ibrutinib-resistant MYD88-mutated lymphoma cells
    Journal Article

    Munshi, M.; Liu, X.; Kofides, A.; Tsakmaklis, N.; Hunter, Z. R.; Guerrera, M. L.; Canning, A.; Gustine, J. N.; Liu, S.; Hatcher, J. M.; more...
    British Journal of Haematology (2024)

    Fulltext@MSK | Save
  • Oral minoxidil for late alopecia in cancer survivors
    Journal Article

    Kuo, A. M. S.; Reingold, R. E.; Ketosugbo, K. F.; Pan, A.; Kraehenbuehl, L.; Dusza, S.; Gajria, D.; Lake, D. E.; Bromberg, J. F.; Traina, T. A.; more...
    Breast Cancer Research and Treatment (2024)

    Fulltext@MSK | Save
  • Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
    Review

    Stanchina, M. D.; Montoya, S.; Danilov, A. V.; Castillo, J. J.; Alencar, A. J.; Chavez, J. C.; Cheah, C. Y.; Chiattone, C.; Wang, Y.; Thompson, M.; more...
    Nature Reviews Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance
    Journal Article

    Gonzalez-Martinez, D.; Roth, L.; Mumford, T. R.; Guan, J.; Le, A.; Doebele, R. C.; Huang, B.; Tulpule, A.; Niewiadomska-Bugaj, M.; Bivona, T. G.; more...
    Nature Communications (2024)

    Fulltext@MSK | Save
  • uPAR immuno-PET in pancreatic cancer, aging, and chemotherapy-induced senescence
    Journal Article

    Pratt, E. C.; Mezzadra, R.; Kulick, A.; Kaminsky, S.; Samuels, Z. V.; Loor, A.; de Stanchina, E.; Lowe, S. W.; Lewis, J. S.
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • Androgen deprivation therapy drives a distinct immune phenotype in localized prostate cancer
    Journal Article

    Dallos, M. C.; Obradovic, A. Z.; McCann, P.; Chowdhury, N.; Pratapa, A.; Aggen, D. H.; Gaffney, C.; Autio, K. A.; Virk, R. K.; De Marzo, A. M.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • GDF-15 predicts epithelioid hemangioendothelioma aggressiveness and is downregulated by sirolimus through ATF4/ATF5 suppression
    Journal Article

    Stacchiotti, S.; Martini, S.; Pasquali, S.; Frezza, A. M.; Beretta, A.; Percio, S.; Lecchi, M.; Tortoreto, M.; Barisella, M.; Collini, P.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • MEK inhibitors lead to PDGFR pathway upregulation and sensitize tumors to RAF dimer inhibitors in NF1-deficient malignant peripheral nerve sheath tumor
    Journal Article

    Miranda-Román, M. A.; Lee, C. J.; Fishinevich, E.; Ran, L.; Patel, A. J.; Yan, J.; Khudoynazarova, M. N.; Warda, S.; Pachai, M. R.; Chen, Y.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save